09:39 AM EST - Eupraxia Pharmaceuticals Inc. : Announced the first patient dosed in the Phase 2b randomized, placebo-controlled portion of the RESOLVE clinical trial evaluating EP-104GI, an investigational treatment for eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading unchanged at $7.60.
